Development of Novel Cancer Immunotherapy Targeting Mutated Genes: Identification of Antigen Epitopes Derived from the Mutated KRAS and EGFR Genes.

• Project/Area Number: 23591913
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Kurume University
• Principal Investigator: SASADA Tetsuro 久留米大学, 医学部, 准教授 (70293967)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: 免疫療法 / 突然変異遺伝子 / T細胞エピトープ / ペプチドワクチン / 上皮成長因子受容体（EGFR) / KRAS / 上皮成長因子受容体（EGFR） / Ｔ細胞エピトープ

Research Abstract

Personalized cancer treatments targeting oncogenic mutated genes are currently developing. Since mutated genes are recognized as foreign by the host immune system, they might be an appropriate target for cancer immunotherapy. In the current study, we have identified two antigen epitopes derived from the epidermal growth factor receptor (EGFR) T790M mutation, which is known to cause resistance to gefitinib in non-small cell lung cancer, and one antigen epitope derived from the KRAS (G12V) mutation, which is frequently detected in colorectal cancer. Our results could provide a novel immunotherapeutic approach for treatment against refractory advanced cancer patients with these mutations, and might lead to development of "personalized immunotherapy targeting mutated genes".

Research Products

• [Journal Article] Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients (2014)
  • Author(s): Kawano K, Tsuda N, Matsueda S, Sasada T, Watanabe N, Ushijima K, Yamaguchi T, Yokomine M, Itoh K, Yamada A, Kamura T.
  • Journal Title: Immunopharmacol Immunotoxicol Volume: (in press)
• [Journal Article] Personalized peptide vaccine for treatment of advanced cancer (2014)
  • Author(s): Sasada T, Yamada A, Noguchi M, Itoh K.
  • Journal Title: Curr Med Chem. Volume: (Epub ahead of print)
  • Peer Reviewed
• [Journal Article] Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib. (2014)
  • Author(s): Azuma K, Komatsu N, Hattori S, Matsueda S, Kawahara A, Sasada T, Itoh K, Hoshino T.
  • Journal Title: PLoS One. Volume: 9 Issue: 1 Pages: e86667-e86667
  • DOI: 10.1371/journal.pone.0086667
  • Peer Reviewed
• [Journal Article] Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. (2014)
  • Author(s): Kawano K, Tsuda N, Matsueda S, Sasada T, Watanabe N, Ushijima K, Yamaguchi T, Yokomine M, Itoh K, Yamada A, Kamura T.
  • Journal Title: Immunopharmacol Immunotoxicol. Volume: 36 Issue: 3 Pages: 224-236
  • DOI: 10.3109/08923973.2014.913617
  • Peer Reviewed / Open Access
• [Journal Article] Personalized Peptide Vaccine for Treatment of Advanced Cancer. (2014)
  • Author(s): Sasada T, Yamada A, Noguchi M, Itoh K.
  • Journal Title: Curr Med Chem. Volume: 21 Issue: 21 Pages: 2332-2345
  • DOI: 10.2174/0929867321666140205132936
  • Peer Reviewed
• [Journal Article] EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation (2013)
  • Author(s): Yamada T
  • Journal Title: PLOS ONE Volume: 8 Issue: 11 Pages: e78389-e78389
  • DOI: 10.1371/journal.pone.0078389
  • Peer Reviewed
• [Journal Article] Personalized peptide vaccination : a new approach for advanced cancer as therapeutic cancer vaccine (2013)
  • Author(s): Noguchi M, Sasada T, Itoh K.
  • Journal Title: Cancer Immunol Immunother Volume: 62 Pages: 919-29
  • Peer Reviewed
• [Journal Article] A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients : Prolongation of prostate-specific antigen doubling time. (2013)
  • Author(s): Noguchi M, Moriya F, Suekane S, Ohnishi R, Matsueda S, Sasada T, Yamada A, Itoh K.
  • Journal Title: BMC Cancer Volume: 13 Issue: 1 Pages: 613-613
  • DOI: 10.1186/1471-2407-13-613
  • Peer Reviewed
• [Journal Article] Current status of immunotherapy for the treatment of biliary tract cancer (2013)
  • Author(s): Takahashi R, Yoshitomi M, Yutani S, Shirahama T, Noguchi M, Yamada A, Itoh K, Sasada T.
  • Journal Title: Hum Vaccin Immunother Volume: 9(5) Pages: 1069-1072
  • Peer Reviewed
• [Journal Article] A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients (2013)
  • Author(s): Yutani S, Komatsu N, Yoshitomi M, Matsueda S, Yonemoto K, Mine T, Noguchi M, Ishihara Y, Yamada A, Itoh K, Sasada T.
  • Journal Title: Oncol Rep. Volume: 30(3) Pages: 1094-100
  • Peer Reviewed
• [Journal Article] Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients (2013)
  • Author(s): Takahashi R, Ishibashi Y, Hiraoka K, Matsueda S, Kawano K, Kawahara A, Kage M, Ohshima K, Yamanaka R, Shichijo S, Shirouzu K, Itoh K, Sasada T.
  • Journal Title: Cancer Sci. Volume: 104(10) Pages: 1285-94
  • Peer Reviewed
• [Journal Article] Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine. (2013)
  • Author(s): Yutani S, Komatsu N, Matsueda S, Yoshitomi M, Shirahama T, Yamada A, Itoh K, Sasada T.
  • Journal Title: Evid Based Complement Alternat Med. Volume: 2013 Pages: 981717-981717
  • DOI: 10.1155/2013/981717
  • Peer Reviewed
• [Journal Article] The next generation of peptide vaccines for advanced cancer (2013)
  • Author(s): Yamada A, Sasada T, Noguchi M, Itoh K .
  • Journal Title: Cancer Sci. Volume: 104(1) Pages: 15-21
  • Peer Reviewed
• [Journal Article] Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. (2013)
  • Author(s): Takahashi R, Ishibashi Y, Hiraoka K, Matsueda S, Kawano K, Kawahara A, Kage M, Ohshima K, Yamanaka R, Shichijo S, Shirouzu K, Itoh K, Sasada T.
  • Journal Title: Cancer Sci. Volume: 104 Issue: 10 Pages: 1285-1294
  • DOI: 10.1111/cas.12226
  • Peer Reviewed
• [Journal Article] A Phase II study of personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients (2013)
  • Author(s): Yutani S., Komatsu N., Yoshitomi M., 他8名
  • Journal Title: Oncology Report Volume: 30 Issue: 3 Pages: 1094-1100
  • DOI: 10.3892/or.2013.2556
  • Peer Reviewed
• [Journal Article] テーラーメイドがんペプチドワクチン療法 (2013)
  • Author(s): 笹田哲朗
  • Journal Title: ライフライン21 がんの先進医療 Volume: 11 Pages: 45-48
• [Journal Article] Next generation peptide vaccines for advanced cancer. (2013)
  • Author(s): Yamada A, Sasada T, Noguchi M, Itoh K.
  • Journal Title: Cancer Sci Volume: 104(1) Issue: 1 Pages: 15-21
  • DOI: 10.1111/cas.12050
  • Peer Reviewed
• [Journal Article] Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. (2013)
  • Author(s): Noguchi M, Sasada T, Itoh K.
  • Journal Title: Cancer Immunol Immunother. Volume: 62 Issue: 5 Pages: 919-29
  • DOI: 10.1007/s00262-012-1379-1
  • Peer Reviewed
• [Journal Article] Current status of immunotherapy for the treatment of biliary tract cancer. (2013)
  • Author(s): Takahashi R, Yoshitomi M, Yutani S, Shirahama T, Noguchi M, Yamada A, Itoh K, Sasada T.
  • Journal Title: Hum Vaccin Immunother. Volume: 9
  • Peer Reviewed
• [Journal Article] Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized Peptide vaccinations for advanced castration-resistant prostate cancer. (2013)
  • Author(s): Pang X, Tashiro K, Eguchi R, Komatsu N, Sasada T, Itoh K, Kuhara S.
  • Journal Title: Biosci Biotechnol Biochem. Volume: 77 Pages: 766-70
  • NAID: 10031170716
  • Peer Reviewed
• [Journal Article] Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. (2013)
  • Author(s): Matsueda S, Komatsu N, Kusumoto K, Koga S, Yamada A, Kuromatsu R, Yamada S, Seki R, Yutani S, Shichijo S, Mine T, Fukuda T, Okamura T, Okuda S, Sata M, Honda J, Kaji M, Itoh K, Sasada T.
  • Journal Title: Dev Comp Immunol. Volume: 41(1) Issue: 1 Pages: 68-76
  • DOI: 10.1016/j.dci.2013.04.004
  • Peer Reviewed
• [Journal Article] Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination (2012)
  • Author(s): Komatsu K, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Yamada A, Doi A, Suekane S, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T.
  • Journal Title: Cancer Volume: 118(12) Pages: 3208-21
  • Peer Reviewed
• [Journal Article] Personalized peptide vaccination in patients with refractory non-small cell lung cancer (2012)
  • Author(s): Yoshiyama K, Terazaki Y, Satoko Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Sasada T, Takamori S.
  • Journal Title: Int J Oncol Volume: 40 Pages: 1492-500
  • Peer Reviewed
• [Journal Article] Personalized peptide vaccination for advanced biliary tract cancer : IL-6, nutritional status, and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis (2012)
  • Author(s): Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H.
  • Journal Title: Exp Ther Med. Volume: 3(3) Pages: 463-469
  • Peer Reviewed
• [Journal Article] Phase II study of personalized peptide vaccination in patients with castration-resistant prostate cancer evaluating progression status with or without prior docetaxel-based chemotherapy (2012)
  • Author(s): Noguchi M, Moriya F, Suekane S, Arai G, Yoshihara K, Ioji T, Matsueda S, Sasada T, Yamada A, Itoh K.
  • Journal Title: Prostate Volume: 72(8) Pages: 834-45
  • Peer Reviewed
• [Journal Article] Immunological Evaluation of Personalized Peptide Vaccination in Refractory Small Cell Lung Cancer (2012)
  • Author(s): Terazaki Y, Yoshiyama K, Matsueda S, Watanabe N, Kawahara A, Naito Y, Suekane S, Komatsu N, Ioji T, Yamada A, Mine T, Terasaki M, Itoh K, Takamori S, Sasada T.
  • Journal Title: Cancer Sci. Volume: 103(4) Pages: 638-44
  • Peer Reviewed
• [Journal Article] Personalized peptide vaccination : a novel immunotherapeutic approach for advanced cancer (2012)
  • Author(s): Sasada T, Noguchi M, Yamada A, Itoh K.
  • Journal Title: Hum Vaccin Immunother Volume: 8(9) Pages: 1309-1313
  • Peer Reviewed
• [Journal Article] Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer. (2012)
  • Author(s): Sasada T, Noguchi M, et al.
  • Journal Title: Hum Vaccin Immunother Volume: 8 Issue: 9 Pages: 1309-1313
  • DOI: 10.4161/hv.20988
  • Peer Reviewed
• [Journal Article] Identification of B cell epitopes reactive to human papillomavirus type-16 L1- derived peptides. (2012)
  • Author(s): Fukui A, Matsueda S, Kawano K, Tsuda N, Komatsu N, Shichijo S, Sasada T, Hattori S, Ushijima K, Itoh K, Kamura T.
  • Journal Title: Virol J. Volume: 9 Issue: 1 Pages: 199-199
  • DOI: 10.1186/1743-422x-9-199
  • Peer Reviewed
• [Journal Article] Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. (2012)
  • Author(s): Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T.
  • Journal Title: Eur J Radiol. Volume: 81 Issue: 12 Pages: 4179-84
  • DOI: 10.1016/j.ejrad.2012.07.009
  • Peer Reviewed
• [Journal Article] Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. (2012)
  • Author(s): Terazaki Y, Yoshiyama K, Matsueda S, Watanabe N, Yamada A, Mine T, Terasaki M, Itoh K, Takamori S, Sasada T.
  • Journal Title: Cancer Sci Volume: 103(4) Issue: 4 Pages: 638-644
  • DOI: 10.1111/j.1349-7006.2012.02202.x
  • Peer Reviewed
• [Journal Article] Personalized peptide vaccination in patients with refractory non-small cell lung cancer. (2012)
  • Author(s): Yoshiyama K, Terazaki Y, Satoko Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Sasada T and Takamori S.
  • Journal Title: Int J Oncol Volume: 40 Pages: 1492-1500
  • DOI: 10.3892/ijo.2012.1351
  • Peer Reviewed
• [Journal Article] Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination (2012)
  • Author(s): Komatsu N, Noguchi M, et al
  • Journal Title: Cancer Volume: (In press) Issue: 12 Pages: 3208-3221
  • DOI: 10.1002/cncr.26636
  • Peer Reviewed
• [Journal Article] Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status, and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. (2012)
  • Author(s): Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H.
  • Journal Title: Exp Ther Med Volume: 3 Issue: 3 Pages: 463-469
  • DOI: 10.3892/etm.2011.424
  • Peer Reviewed
• [Journal Article] Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination (2011)
  • Author(s): Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani Y, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K.
  • Journal Title: Cancer Biol Ther. Volume: 10 Pages: 1266-79
  • Peer Reviewed
• [Journal Article] Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. (2011)
  • Author(s): Sasada T, Suekane S.
  • Journal Title: Immunotherapy Volume: 3 Pages: 1235-51
  • Peer Reviewed
• [Journal Article] Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy (2011)
  • Author(s): Noguchi M, et al
  • Journal Title: Prostate Volume: 71 Issue: 8 Pages: 470-479
  • DOI: 10.1002/pros.21485
  • Peer Reviewed
• [Journal Article] がん免疫療法―最近のトピックと今後の展望― (2011)
  • Author(s): 笹田哲朗
  • Journal Title: 久留米医学会雑誌 Volume: 74 Pages: 221-228
• [Presentation] EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer (2013)
  • Author(s): Sasada T, et al.
  • Organizer: 28th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
  • Place of Presentation: National Harbor, MD, USA
  • Year and Date: 2013-11-08
• [Presentation] EGFR T790M-derived T Cell Epitopes as a Target for Immunotherapy against EGFR-TKI-resistant Non-Small Cell Lung Cancer (2013)
  • Author(s): Yamada T, Sasada T, et al.
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜市
  • Year and Date: 2013-10-05
• [Presentation] EGFR T790M Mutation as a Novel Target for Immunotherapy against EGFR-TKI-resistant Non-Small Cell Lung Cancer (2013)
  • Author(s): Yamada T, Sasada T, et al.
  • Organizer: 第17回日本がん免疫学会総会
  • Place of Presentation: 宇部市
  • Year and Date: 2013-07-05
• [Presentation] 標準治療抵抗性大腸癌に対するテーラーメイド癌ペプチドワクチン療法の検討 (2013)
  • Author(s): 山田哲平、笹田哲朗、伊東恭悟
  • Organizer: 第117回日本外科学会定期学術集会
  • Place of Presentation: 福岡市
• [Presentation] Phase II study of personalized peptide vaccination for cisplatin-based chemotherapy resistant advanced urothelial carcinoma patients. (2013)
  • Author(s): Suekane S, Noguchi M, Moriya F, Sasada T, Matsuoka K Itoh K.
  • Organizer: 2013 AUA Annual Meeting
  • Place of Presentation: San Diego, CA, USA
• [Presentation] 膵臓癌に対する十全大補湯のテーラーメイドペプチドワクチン療法への免疫増強効果の検討 (2013)
  • Author(s): 山田哲平、笹田哲朗、伊東恭悟
  • Organizer: 第68回日本消化器外科学会総会
  • Place of Presentation: 宮崎市
• [Presentation] 去勢抵抗性前立腺がんに対するペプチドワクチン療法 (2013)
  • Author(s): 野口正典、末金茂高、守屋普久子、笹田哲朗、山田 亮、伊東恭悟
  • Organizer: 第11回日本臨床腫瘍学会学術総会
  • Place of Presentation: 仙台市
  • Invited
• [Presentation] 去勢抵抗性前立腺がんに対するペプチドワクチン療法 (2013)
  • Author(s): 野口正典、末金茂高、守屋普久子、笹田哲朗、山田 亮、伊東恭悟
  • Organizer: 第78回日本泌尿器科学会東部総会
  • Place of Presentation: 新潟市
  • Invited
• [Presentation] EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer. (2013)
  • Author(s): Sasada T, Yamada T, Azuma K, Matsueda S, Itoh K.
  • Organizer: 28th Annual Meeting of Society for Immunotherapy of Cancer (SITC).
  • Place of Presentation: National Harbor, MD, USA
• [Presentation] Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination. (2013)
  • Author(s): Komatsu N, Pang X, Araki H, Koda Y, Soejima K, Sasada T, Tashiro K, Kuhara S, Itoh1 K.
  • Organizer: 28th Annual Meeting of Society for Immunotherapy of Cancer (SITC).
  • Place of Presentation: National Harbor, MD, USA
• [Presentation] Phase I trial of a novel cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer. (2013)
  • Author(s): Noguchi M, Arai G, Matsumoto K, Naito S, Moriya F, Suekane S, Sasada T, Yamada A, Itoh K.
  • Organizer: 33rd Congress of the Societe Internationale d’Urologie (SIU).
  • Place of Presentation: Vancouver, BC, USA
• [Presentation] Personalized peptide vaccination in combination with chemotherapyfor patients with advanced colorectal cancer. (2012)
  • Author(s): Tetsuro Sasada,Shigeru Yutani, Satoko Matsueda, Nobukazu Komatsu, Kyogo Itoh.
  • Organizer: Society for Immunotherapy of Cancer (SITC) 2012 Meeting
  • Place of Presentation: North Bethesda, USA
• [Presentation] Identification of Predictive Biomarkers in Cancer Patients Receiving Personalized Peptide Vaccination. (2011)
  • Author(s): Sasada T, Matsueda S, Shichijo S, Ioji T, Komatsu N, Noguchi M, Yamada A, Itoh K.
  • Organizer: 26th Annual Meeting of Society for Immunotherapy of Cancer.
  • Place of Presentation: Bethesda, MD, USA
• [Presentation] Predictive Biomarker in Cancer Patients Receiving Personalized Peptide Vaccination. (2011)
  • Author(s): Sasada T, Matsueda S, Shichijo S, Komatsu N, Noguchi M, Yamada A, Itoh K.
  • Organizer: 第70回日本癌学会総会
  • Place of Presentation: 名古屋
• [Presentation] Identification of Predoctive Biomarkers in cancer patients receiving personalized peptide vaccination (2011)
  • Author(s): 笹田哲朗、松枝智子、七條茂樹、小松誠和、五百路徹也、野口正典、山田亮、伊東恭悟
  • Organizer: 第15回日本癌免疫学会
  • Place of Presentation: 大阪
• [Presentation] 再燃前立腺がんを対象としたテーラーメイドペプチドワクチン療法における一塩基多型(SNPs)解析による予後予測マーカーの探索
  • Author(s): 小松誠和、Xiaoliang Pang、荒木啓充、高木真理、宮田有英、松枝智子、笹田哲朗、田代康介、久原哲、伊東恭悟
  • Organizer: 第17回日本がん免疫学会総会
  • Place of Presentation: 宇部市
• [Presentation] EGFR T790M Mutation as a Novel Target for Immunotherapy against EGFR-TKI-resistant Non-Small Cell Lung Cancer.
  • Author(s): Teppei YAMADA, Koichi AZUMA, Shunichi SUGAWARA, Satoko MATSUEDA, Yuichi YAMASHITA, Kyogo ITOH, Tetsuro SASADA
  • Organizer: 第17回日本がん免疫学会総会
  • Place of Presentation: 宇部市
• [Presentation] 再燃前立腺がん患者の遺伝子発現プロファイルに基づくテーラーメイドペプチドワクチン適格性診断マーカーの同定
  • Author(s): 荒木啓充、Pang Xiaoliang、高木真理、宮田有英、小松誠和、松枝智子、伊東恭悟、笹田哲朗、田代康介、久原哲
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜市
• [Presentation] ヒトパピローマウイルス様粒子ワクチン投与により免疫原性を示すHPV16型L1由来ペプチドエピトープの同定
  • Author(s): 松枝智子、横峯正人、福井章正、河野光一郎、津田尚武、七條茂樹、笹田哲朗、牛島公生、伊東恭悟、嘉村敏治
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜市
• [Presentation] EGFR T790M-derived T Cell Epitopes as a Target for Immunotherapy against EGFR-TKI-resistant Non-Small Cell Lung Cancer
  • Author(s): Teppei Yamada, Koichi Azuma, Shunichi Sugawara, Satoko Matsueda, Yuichi Yamashita, Kyogo Itoh, Tetsuro Sasada
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜市
• [Presentation] 去勢抵抗性前立腺がん患者を対象とした20ペプチド混合ワクチンの第1相臨床試験
  • Author(s): 山田亮、野口正典、笹田哲朗、小松誠和、松枝智子、伊東恭悟
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜市
• [Presentation] 乳癌テーラーメイドペプチドワクチン療法後の免疫組織学的検討
  • Author(s): 唐宇飛、高橋龍司、岩熊伸高、竹中美貴、高良慶子、白水和雄、松枝智子、笹田哲朗、伊東恭悟
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜市
• [Presentation] CTLエピトープワクチン療法
  • Author(s): 伊東恭悟、山田亮、植村天受、笹田哲朗、野口正典
  • Organizer: 第72回日本癌学会学術総会
  • Place of Presentation: 横浜市
  • Invited
• [Presentation] 標準治療抵抗性の進行膵癌に対するテーラーメイド型ペプチドワクチン療法
  • Author(s): 笹田哲朗、吉富宗宏、由谷茂、伊東恭悟
  • Organizer: 第67回日本消化器外科学会総会
  • Place of Presentation: 富山市
• [Presentation] テーラーメイドがんペプチドワクチン：進行がんに対する新規免疫療法
  • Author(s): 笹田哲朗、野口正典、山田亮、小松誠和、松枝智子、伊東恭悟
  • Organizer: 第71回日本癌学会学術総会
  • Place of Presentation: 札幌市
• [Presentation] Personalized peptide vaccination as the second line therapy for patients with chemotherapy-resistant advanced pancreatic cancer.
  • Author(s): Tetsuro Sasada, Shigeru Yutani, Munehiro Yoshitomi, Satoko Matsueda, Nobukazu Komatsu, Kyogo Itoh.
  • Organizer: American Association for Cancer Research (AACR) Annual Meeting 2012
  • Place of Presentation: Chicago, USA
• [Presentation] 癌ペプチドワクチン療法における新規バイオマーカーの探索
  • Author(s): 笹田哲朗、伊東恭悟
  • Organizer: 第112回日本外科学会総会
  • Place of Presentation: 千葉市
• [Book] Personalized peptide vaccine as a novel immunotherapy against advanced cancer, Molecular Vaccines - From Prophylaxis to Therapy (2013)
  • Author(s): Komatsu N, Matsueda S, Noguchi M, Yamada A, Itoh K, Sasada T.
  • Publisher: In Giese Med
• [Book] Molecular Vaccines - From Prophylaxis to Therapy. (2013)
  • Author(s): Komatsu N, Matsueda S, Noguchi M, Yamada A, Itoh K, Sasada T
  • Total Pages: 447
  • Publisher: Springer-Verlag Wien
• [Patent(Industrial Property Rights)] 上皮成長因子受容体のT790M点突然変異配列に由来する抗原ペプチド (2013)
  • Inventor(s): 笹田哲朗、中面哲也、大藤和也
  • Industrial Property Rights Holder: 久留米大学、国立がんセンター
  • Industrial Property Rights Type: 特許
  • Filing Date: 2013-08-08
  • Overseas
• [Patent(Industrial Property Rights)] 上皮成長因子受容体のT790M点突然変異配列に由来する抗原ペプチド (2013)
  • Inventor(s): 笹田哲朗、中面哲也、大藤和也
  • Industrial Property Rights Holder: 久留米大学、国立がんセンター
  • Industrial Property Rights Type: 特許
  • Filing Date: 2013-08-08
  • Overseas
• [Patent(Industrial Property Rights)] 上皮成長因子受容体のT790M点突然変異配列に由来する抗原ペプチド (2012)
  • Inventor(s): 笹田哲朗
  • Industrial Property Rights Holder: 久留米大学
  • Industrial Property Rights Type: 特許
  • Industrial Property Number: 2012-177631
  • Filing Date: 2012-08-10
  • Overseas
• [Patent(Industrial Property Rights)] 上皮成長因子受容体のT790M点突然変異配列に由対する抗原ペプチド (2012)
  • Inventor(s): 笹田哲朗
  • Industrial Property Rights Holder: 久留米大学、久留米リサーチパーク
  • Industrial Property Rights Type: 特許
  • Industrial Property Number: 2012-177631
  • Filing Date: 2012-08-10